Expansion of the pharmaceutical business through the acquisition of Toride Pharma and others as wholly owned subsidiaries
First written in FY2024-Q1. 2 of 3 entries say "Advanced", first in FY2024-Q2. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Regarding the acquisition of shares in Toride Pharma Co., Ltd. and TAT Toride Asset Trading Co., Ltd. by a consolidated subsidiary in June 2023, the payment of contingent consideration was finalized during the current consolidated fiscal year. Accordingly, the consideration paid was recognized additionally as goodwill, on the basis that it had arisen at the acquisition date and that the consideration paid constituted acquisition cost. / Additional acquisition cost (amount recognized as goodwill): ¥174 million」
Payment of contingent consideration related to the acquisition of Toride Pharma and other companies was finalized, and additional acquisition cost of ¥174 million and goodwill were recognized. The company states that no further payment will be required. - FY2024-Q2AdvancedAnnual report
「The provisional accounting treatment for the business combination with Toride Pharma Co., Ltd. and TAT Toride Asset Trading Co., Ltd., conducted on 15 June 2023, was finalized during the second quarter of the current consolidated fiscal year, after having been applied during the first quarter. As a result, the provisionally calculated goodwill of ¥1,020 million decreased by ¥35 million upon finalization of the accounting treatment, to ¥984 million. Goodwill is amortized over 13 years.」
The provisional purchase price allocation for the business combination related to the acquisition of all shares in companies including Toride Pharma was finalized in the second quarter. Goodwill was revised from ¥1,020 million to ¥984 million, with an amortization period of 13 years. - FY2024-Q1First statedAnnual report
「From the first quarter of the current consolidated fiscal year, the companies have been included in the scope of consolidation following the acquisition of all shares in Toride Pharma Co., Ltd. and TAT Toride Asset Trading Co., Ltd. / Business combination date: 15 June 2023 (deemed acquisition date: 30 June 2023) / Voting rights acquired: 100% / Business description: Contract manufacturing and sales of pharmaceutical inspection and packaging services」
The company acquired all shares in Toride Pharma Co., Ltd. and TAT Toride Asset Trading Co., Ltd., making them wholly owned subsidiaries on 15 June 2023. The acquisition cost was ¥1.224 billion and goodwill was ¥1.020 billion, incorporating the contract pharmaceutical packaging and processing business.